Quintiles announced that it has entered into a clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.
According to a release, Quintiles will assume the operational responsibilities for the majority of AstraZeneca’s clinical pharmacology delivery. The alliance is extensive and involves the engagement of a sole provider for clinical pharmacology delivery, and a simple, standardized pricing model. Also, as well as clinical conduct and medical oversight of studies, the agreement covers a range of activities across the end-to-end study process.
Quintiles’ network of clinical pharmacology facilities are located across Europe and the United States, with plans to open a unit in Asia in 2010. These facilities are connected via integrated data platforms using advanced electronic data capture and reporting.
An article that appeared in our June issue, based on a survey of CROs and Pharma managers, discussed this topic of changing relationship structures.
Another example of strategic alliances is between Covance and Lilly from last summer, where Covance took on Lilly’s non-GLP toxicology, in vivo pharmacology, quality control laboratory, and imaging services, and Lilly signed to provide Covance $1.6B in services over 10 years.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.